Amgen
US.AMGN
437.23
-6.89
-1.55%
Amgen
437.23
-6.89
-1.55%
Collector offline (last heartbeat: 19205s ago)
· 2026-09-04 19:59
Pre-market
438.95
-1.16%
After-hours
415.00
-5.08%
Overnight
442.22
-0.43%
Recent news
-
Amgen Advances Tarlatamab Shot Vs. Infusion in Phase 3 Lung Cancer StudyTipRanks · 8/22
-
Amgen | 3: Initial statement of beneficial ownership of securities- Dittrich Thomas J.W.SEC · 9/5
-
Amgen | 4: Statement of changes in beneficial ownership of securities-Officer Busch Matthew C.SEC · 5/12
-
Truist Financial Maintains Amgen(AMGN.US) With Hold RatingMarket Newswire · 8/28
-
Piper Sandler Maintains Amgen(AMGN.US) With Buy Rating, Raises Target Price to $457Market Newswire · 8/20
-
Scotiabank Maintains Amgen(AMGN.US) With Buy Rating, Maintains Target Price $450Market Newswire · 8/28
-
Amgen | 4: Statement of changes in beneficial ownership of securities-Officer Grygiel Nancy A.SEC · 5/12
-
William Blair Maintains Amgen(AMGN.US) With Buy RatingMarket Newswire · 8/27
-
Amgen | 4: Statement of changes in beneficial ownership of securities-Officer Grygiel Nancy A.SEC · 8/8
-
Amgen | 4: Statement of changes in beneficial ownership of securities-Director Klotman Mary E.SEC · 5/22
-
TD Cowen Maintains Amgen(AMGN.US) With Buy Rating, Maintains Target Price $452Market Newswire · 8/27
-
Amgen | 4: Statement of changes in beneficial ownership of securities-Director Garland Greg C.SEC · 5/22
Headlines are aggregated automatically and are not independently verified or edited by our team.
Quote time 2026-09-04 19:59:10
For reference only, not investment advice.